
Anti-VEGF injection needs continue to rise
The demand for anti-VEGF injections to stem vision loss from age-related macular degeneration (AMD) and diabetic retinopathy is continuing to rise by about 15% a year, adding to the strain on district health boards’ (DHBs’) eye care budgets, already burdened by backlogs for eye care such as cataract












